Market Overview

Oppenheimer Reiterates Rating, Raises Price Target On Physicians Realty Trust On Acquisition Update And Equity Offering


In a report published Friday, Oppenheimer analyst Steve Manaker reiterated an Outperform rating on Physicians Realty Trust (NYSE: DOC), and raised the price target from $16.75 to $18.00.

In the report, Oppenheimer noted, “We maintain our Outperform rating and raise our price target to $18 despite lowering our 2015 FFO estimate. Our new price target implies a 13.8% total return, including the 5.8% dividend yield. DOC closed $105 million of acquisitions in 4Q14 and is starting 2015 with $206 million of acquisitions near closing. In order to finance the pipeline, DOC announced the sale of 15 million shares. Previously, we assumed a similar-sized offering but at the end of 2Q15. This change is lowering our 2015 FFO estimate to $1.00 from $1.03, but our 4Q15 estimate remains the same—this is our stable quarterly run-rate FFO est. for DOC assuming $450 million of acquisitions done in the first nine months of 2015.”

Physicians Realty Trust closed on Thursday at $16.64.

Latest Ratings for DOC

Jan 2020MaintainsOverweight
Dec 2019AssumesBuy
Dec 2019UpgradesNeutralBuy

View More Analyst Ratings for DOC
View the Latest Analyst Ratings

Posted-In: Oppenheimer Steve ManakerAnalyst Color Price Target Analyst Ratings


Related Articles (DOC)

View Comments and Join the Discussion!

Latest Ratings

RPAYCantor FitzgeraldMaintains18.0
CMSCredit SuisseDowngrades
PBCTStephens & Co.Maintains15.5
TTECCowen & Co.Initiates Coverage On50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at